Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution

World Journal of Gastroenterology

Volumn 17, Issue 33, 2011, Pages 3802-3809

  Takagi, Tomohisa ^a   Naito, Yuji ^a   Uchiyama, Kazuhiko ^a   Okuda, Toshimitsu ^a   Mizushima, Katsura ^a   Suzuki, Takahiro ^a   Handa, Osamu ^a   Ishikawa, Takeshi ^a   Yagi, Nobuaki ^a   Kokura, Satoshi ^a   Ichikawa, Hiroshi ^a   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Experimental colitis; Extracellular signal regulated kinase; Intestinal epithelial cells; Rebamipide; Rho kinase

Indexed keywords

ENEMA; MITOGEN ACTIVATED PROTEIN KINASE; REBAMIPIDE; RHO KINASE; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DESCENDING COLON; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; IN VITRO STUDY; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE ULCER; MALE; NONHUMAN; PHOSPHORYLATION; RAT; ULCER HEALING; ULCERATIVE COLITIS; WOUND HEALING;

EID: 80053896854     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i33.3802     Document Type: Article

References (44)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205
3. Podolsky DK. Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. Am J Physiol 1999; 277: G495-G499
4. Okamoto R, Watanabe M. Cellular and molecular mechanisms of the epithelial repair in IBD. Dig Dis Sci 2005; 50 Suppl 1: S34-S38
5. van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 2002; 50 Suppl 3: III47-III53
6. Naito Y, Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroen-terol Hepatol 2010; 4: 261-270
7. Skrypnyk IN. Diagnostic and treatment algorithms of ul-cerative colitis in Ukraine. Dig Dis 2009; 27: 550-554
8. Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL. Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol 2000; 95: 1838-1839
9. Makiyama K, Takeshima F, Hamamoto T. Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig Dis Sci 2005; 50: 2323-2329
10. Miyata M, Kasugai K, Ishikawa T, Kakumu S, Onishi M, Mori T. Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig Dis Sci 2005; 50 Suppl 1: S119-S123
11. Matsumoto S, Tsuji K, Shirahama S. Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: open label study. World J Gastroenterol 2008; 14: 4059-4064
12. Lotz MM, Rabinovitz I, Mercurio AM. Intestinal restitution: progression of actin cytoskeleton rearrangements and inte-grin function in a model of epithelial wound healing. Am J Pathol 2000; 156: 985-996
13. Takagi T, Naito Y, Okuda T, Uchiyama K, Adachi S, Mizushi-ma K, Handa O, Kokura S, Ichikawa H, Yoshikawa T. Ecabet sodium promotes the healing of trinitrobenzene-sulfonic-acid-induced ulceration by enhanced restitution of intestinal epithelial cells. J Gastroenterol Hepatol 2010; 25: 1259-1265
14. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96: 795-803
15. Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997; 41: 487-493
16. Petit V, Boyer B, Lentz D, Turner CE, Thiery JP, Vallés AM. Phosphorylation of tyrosine residues 31 and 118 on paxillin regulates cell migration through an association with CRK in NBT-II cells. J Cell Biol 2000; 148: 957-970
17. Bell CJ, Gall DG, Wallace JL. Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol 1995; 268: G622-G630
18. Murai R, Kanbe T, Mukoyama T, Shimomura T, Hashigu-chi K, Yoshida Y, Tsuchiya H, Hoshikawa Y, Kurimasa A, Shiota G. Effect of rectal administration of rebamipide on dextran sulfate sodium-induced colitis: role of hepatocyte growth factor. Infamm Res 2007; 56: 240-245
19. Nakamura M, Takahashi T, Matsumoto T, Atsuda K, Hibi N, Matsui H, Yamada H, Tsuchimoto K. Direct autoradio-graphic evidence that rebamipide interacts with neutrophils in dextran sulfate sodium induced colitis in rats. Dig Dis Sci 2005; 50 Suppl 1: S113-S118
20. Okayama M, Tsubouchi R, Nishio H, Kato S, Takeuchi K. Protective effect of intra-rectal administration of rebamipide on dextran sulfate sodium-induced rat colitis. Digestion 2004; 70: 240-249
21. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, In-aba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet' s disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003; 4: 19-28
22. Ro JY, Kim JY, Kim KH. The inhibitory mechanism of re-bamipide on the mediator release in the guinea pig lung mast cells activated with specific antigen-antibody reactions. Pharmacology 2001; 63: 175-184
23. Saad SY, Najjar TA, Al-Sohaibani MO. The effect of re-bamipide on cisplatin-induced nephrotoxicity in rats. Pharmacol Res 2000; 42: 81-86
24. Hong KW, Kim KE, Rhim BY, Lee WS, Kim CD. Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci 1998; 43: 154S-159S
25. Lee SM, Kim KH. Rebamipide ameliorates hepatic dysfunction induced by ischemia/reperfusion in rats. Eur J Pharmacol 1995; 294: 41-46
26. Tokuhara K, Hamada Y, Tanaka H, Yamada M, Ozaki T, Matsui K, Kamiyama Y, Nishizawa M, Ito S, Okumura T. Rebamipide, anti-gastric ulcer drug, up-regulates the induction of iNOS in proinflammatory cytokine-stimulated hepa-tocytes. Nitric Oxide 2008; 18: 28-36
27. Ríos JD, Shatos M, Urashima H, Tran H, Dartt DA. OPC-12759 increases proliferation of cultured rat conjuncti-val goblet cells. Cornea 2006; 25: 573-581
28. Urashima H, Okamoto T, Takeji Y, Shinohara H, Fujisawa S. Rebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treat-ed in vivo model. Cornea 2004; 23: 613-619
29. Tanito M, Takanashi T, Kaidzu S, Yoshida Y, Ohira A. Cy-toprotective effects of rebamipide and carteolol hydrochlo-ride against ultraviolet B-induced corneal damage in mice. Invest Ophthalmol Vis Sci 2003; 44: 2980-2985
30. Sakurai K, Osaka T, Yamasaki K. Protection by rebamipide against acetic acid-induced colitis in rats: relationship with its antioxidative activity. Dig Dis Sci 1998; 43: 125S-133S
31. Iwai A, Iwashita E. Changes in colonic inflammation induced by dextran sulfate sodium (DSS) during short- and long-term administration of rebamipide. Dig Dis Sci 1998; 43: 143S-147S
32. Kishimoto S, Haruma K, Tari A, Sakurai K, Nakano M, Nakagawa Y. Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Dig Dis Sci 2000; 45: 1608-1616
33. Nakashima T, Maeda T, Nagamoto H, Kumakura T, Takai M, Mori T. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats. Dig Dis Sci 2005; 50 Suppl 1: S124-S131
34. Takahashi M, Takada H, Takagi K, Kataoka S, Soma R, Ku-wayama H. Gastric restitution is inhibited by dexametha-sone, which is reversed by hepatocyte growth factor and re-bamipide. Aliment Pharmacol Ther 2003; 18 Suppl 1: 126-132
35. Taupin D, Podolsky DK. Trefoil factors: initiators of muco-sal healing. Nat Rev Mol Cell Biol 2003; 4: 721-732
36. Wong WM, Playford RJ, Wright NA. Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy? Gut 2000; 46: 286-292
37. Gazel A, Nijhawan RI, Walsh R, Blumenberg M. Transcrip-tional profling defnes the roles of ERK and p38 kinases in epidermal keratinocytes. J Cell Physiol 2008; 215: 292-308
38. Wang Z, Yang H, Tachado SD, Capó-Aponte JE, Bildin VN, Koziel H, Reinach PS. Phosphatase-mediated crosstalk control of ERK and p38 MAPK signaling in corneal epithelial cells. Invest Ophthalmol Vis Sci 2006; 47: 5267-5275
39. Tanigawa T, Pai R, Arakawa T, Tarnawski AS. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci 2007; 52: 240-247
40. Cetin S, Ford HR, Sysko LR, Agarwal C, Wang J, Neal MD, Baty C, Apodaca G, Hackam DJ. Endotoxin inhibits intestinal epithelial restitution through activation of Rho-GTPase and increased focal adhesions. J Biol Chem 2004; 279: 24592-24600
41. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514
42. Santos MF, McCormack SA, Guo Z, Okolicany J, Zheng Y, Johnson LR, Tigyi G. Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. J Clin Invest 1997; 100: 216-225
43. Rao JN, Guo X, Liu L, Zou T, Murthy KS, Yuan JX, Wang JY. Polyamines regulate Rho-kinase and myosin phosphory-lation during intestinal epithelial restitution. Am J Physiol Cell Physiol 2003; 284: C848-C859
44. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, Narumiya S. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000; 57: 976-983